

# Mark Voskoboynik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4426966/publications.pdf>

Version: 2024-02-01

22  
papers

215  
citations

1040056

9  
h-index

1058476

14  
g-index

22  
all docs

22  
docs citations

22  
times ranked

479  
citing authors

#	ARTICLE	IF	CITATIONS
1	First-in-human phase 1 study of MK-0753, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. <i>Cancer</i> , 2020, 126, 4926-4935.	4.1	46
2	Prospective analysis of 895 patients on a UK Genomics Review Board. <i>ESMO Open</i> , 2019, 4, e000469.	4.5	22
3	A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1177-1189.	4.3	21
4	Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence. <i>Biochemistry Research International</i> , 2014, 2014, 1-9.	3.3	18
5	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. <i>British Journal of Cancer</i> , 2017, 117, 938-946.	6.4	18
6	Clinicopathological characteristics associated with BRAF <sup>K601E</sup> and BRAF <sup>L597</sup> mutations in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 222-228.	3.3	16
7	A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 434-446.	1.9	16
8	Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. <i>Clinical Lung Cancer</i> , 2021, 22, e425-e430.	2.6	15
9	Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 150-156.	0.8	11
10	An update on adjuvant systemic therapies in melanoma. <i>Melanoma Management</i> , 2019, 6, MMT28.	0.5	10
11	Charting a new course for prostate cancer™ currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1253-1256.	2.4	7
12	Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2579-2579.	1.6	4
13	Cardiovascular disease and malignant melanoma. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, .	1.2	3
14	Early Cardiovascular Death in Patients with Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 1572-1573.	27.0	2
15	Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2022, 40, 434-434.	1.6	2
16	Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. <i>JCO Precision Oncology</i> , 2021, 5, 561-568.	3.0	1
17	ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). <i>Journal of Clinical Oncology</i> , 2022, 40, TPS205-TPS205.	1.6	1
18	Abstract CT041: Monotherapy dose escalation of davocetcept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1). <i>Cancer Research</i> , 2022, 82, CT041-CT041.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).. Journal of Clinical Oncology, 2022, 40, 2560-2560.	1.6	1
20	Immunotherapy for bladder cancer: rediscovering an old friend. BJU International, 2016, 117, 721-724.	2.5	0
21	Setting the Stage. Chest, 2019, 156, 633-634.	0.8	0
22	Improving regional access: Phase 1 teletrials in the era of COVID-19. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 416-417.	1.1	0